Haleon plc 6-K, filed Nov 10, 2025
Haleon plc (HLN)
6-K
2025-11-10
For: 2025-11-10
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on November 10, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
10
November 2025 - “Appointment of Vindi Banga as
Chair”
|
99.1
Haleon plc: Appointment of Vindi Banga as Chair
10 November 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the
resignation of Sir Dave Lewis as Chair and appointment of Vindi
Banga.
Dave Lewis will step down as Chair of the Board and as a Director
of the Company on 31 December 2025 in order to pursue a new
executive role. The Board is pleased to announce the appointment of
Vindi Banga as Chair to succeed Dave with effect from 1 January
2026.
Vindi has served as Senior Independent Director on the Haleon Board
since the Company's listing in 2022. The Board was unanimous in its
appointment of Vindi given his wealth of global corporate and
commercial leadership experience. He has an extensive track record
of delivering outstanding performance in highly competitive global
consumer-focused businesses and a deep understanding of operating
across developed and emerging markets. He spent 33 years at
Unilever plc, where he was also CEO and Chair of Hindustan Unilever
Ltd, one of India's largest listed companies, and was also
responsible for Global Home & Personal Care, Foods and Ice
Cream and a member of the Unilever Executive Board.
Vindi also has extensive international Board experience. He is
currently Chair of UK Government Investments Limited (UKGI) and has
previously served as Senior Independent Director at GSK and Marks
and Spencer plc. Vindi is a partner at CD&R, a leading private
investment firm where he has chaired and served on the boards of
several of the firm's portfolio companies. He is Chair of Council
of Imperial College London.
Vindi's remuneration and the appointment of a successor as Senior
Independent Director will be announced in due course and before
Vindi's appointment as Chair takes effect.
Sir Dave Lewis commented: "After more than three years Haleon is now
well established as an independent listed company. The Board and
Executive team are strong and the business is performing well in a
tough environment. The leverage at demerger has been effectively
addressed, the large overhang managed smoothly and the portfolio
reshaping is progressing.
My decision to step down is a personal one and is related to a new
unique opportunity which I wish to take forward. I would like to
thank my Board colleagues, Brian and his team for their support and
commitment. It has been a privilege to be part of Haleon and I am
confident that the business has a bright future."
Vindi Banga commented: "On
behalf of the Board, I would like to thank Dave for his leadership
and the considerable contribution he has made as Chair of Haleon
since its listing in July 2022. It is a privilege to Chair Haleon
and I look forward to working with the Board and management team to
support Haleon's continued development."
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.6R.
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
About Vindi Banga
https://www.haleon.com/who-we-are/leadership#manvinder-singh-banga
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
November 10, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|